Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
Chan, Arlene, Prof, Delaloge, Suzette, MD, Holmes, Frankie A, MD, Moy, Beverly, MD, Iwata, Hiroji, MD, Harvey, Vernon J, MD, Robert, Nicholas J, MD, Silovski, Tajana, MD, Gokmen, Erhan, MD, von Minckwitz, Gunter, Prof, Ejlertsen, Bent, MD, Chia, Stephen K L, MD, Mansi, Janine, MD, Barrios, Carlos H, Prof, Gnant, Michael, Prof, Buyse, Marc, ScD, Gore, Ira, MD, Smith, John, MD, Harker, Graydon, MD, Masuda, Norikazu, MD, Petrakova, Katarina, MD, Zotano, Angel Guerrero, MD, Iannotti, Nicholas, MD, Rodriguez, Gladys, MD, Tassone, Pierfrancesco, Prof, Wong, Alvin, PharmD, Bryce, Richard, MBChB, Ye, Yining, PhD, Yao, Bin, MS, Martin, Miguel, Prof
Published in The lancet oncology (01.03.2016)
Published in The lancet oncology (01.03.2016)
Get full text
Journal Article